Cellular Biomedicine Group Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into Allegations of Corporate Wrongdoing

News provided by

Dunnam & Dunnam

15 Apr, 2015, 11:30 ET

NEW YORK, April 15, 2015 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating allegations for Cellular Biomedicine Group Inc. shareholders (NASDAQ: CBMG). Concerned CBMG investors who purchased shares are encouraged to contact securities attorney Hamilton Lindley by clicking here.

The law firm's investigation will focus on potential violations of the federal securities laws by Cellular Biomedicine Group Inc. A report was published in SeekingAlpha.com on April 7, 2015 stating that (1) Cellular Biomedicine has achieved an unsustainable $500m valuation by using paid stock promoters; (2) its "Car-T" technology has experienced patient deaths and is worthless; (3) its founders have been the target of multiple allegations of dishonesty; and (4) there are numerous accounting and financial irregularities in its corporate structure and SEC filings.  Shares of CBMG have fallen, on this news, as much as $6.30 per share, or more than 24%, to as low as $25.92 in intraday trading on April 7, 2015.

Dunnam & Dunnam has significant experience representing shareholders in securities lawsuits nationwide. CBMG stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at [email protected] with questions, toll free at (844) 702-2990 or visit http://www.dunnamlaw.com/CBMG.

Find these Waco car accident lawyers on social media on Google+, LinkedIn, Facebook, and Twitter.

SOURCE Dunnam & Dunnam

Related Links

http://www.dunnamlaw.com

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.